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Warfarin is a widely used anticoagulant that has a narrow therapeutic range because of both genetic and environmental factors.
CYP2C9*2 (p.R144C), CYP2C9*3 (p.I359L), and the VKORC1 promoter (g.-1639G/A) polymorphisms occur frequently in patients
who are warfarin ‘‘sensitive’’ and require lower doses, whereas patients with VKORC1 missense mutations are warfarin ‘‘resistant’’ and
require higher doses. To compare the CYP2C9 and VKORC1 allele and genotype frequencies among 260 Ashkenazi (AJ) and 80 Sephardi
Jewish (SJ) individuals, we genotyped six CYP2C9 and eight VKORC1 alleles by using the Tag-It Mutation Detection Kit and PCR-RFLP
assays. The ‘‘sensitive’’ CYP2C9*2 and *3 alleles had signiﬁcantly higher frequencies in SJ than in AJ individuals, 0.194 and 0.144 versus
0.127 and 0.081, respectively (p% 0.001). In contrast, the VKORC1 p.D36Ymutation, which predicts warfarin ‘‘resistance,’’ had a signif-
icantly higher frequency in AJ than in SJ individuals, 0.043 versus 0.006, respectively (p% 0.025). Of note, 11.3% of AJ individuals pre-
dicted to beCYP2C9 extensivemetabolizers and 8.7% of those predicted to be intermediate and poormetabolizers wereVKORC1 p.D36Y
carriers who require markedly higher warfarin doses. Thus, ~10% of all AJ individuals would be misclassiﬁed when only genotyping
CYP2C9*2, *3, and VKORC1 g.-1639G/A, underscoring the importance of screening for p.D36Y prior to initiating warfarin anticoagu-
lation in AJ individuals. Taken together, our ﬁndings show that ~85% of AJ and ~90% of SJ individuals have at least one ‘‘sensitive’’
(CYP2C9*2, *3, VKORC1 g.-1639G/A) or ‘‘resistant’’ (VKORC1 p.D36Y) allele, indicating that each group has different warfarin phar-
macogenetics and would beneﬁt from genotype-based dose predictions.Warfarin is one of themost widely used anticoagulants, yet
interindividual differences in drug response, a narrow ther-
apeutic range, and a high risk of bleeding or stroke compli-
cate its clinical use.1–3 The metabolism and anticoagulant
action of warfarin presumably are moderated by many
genes; however, the polymorphic cytochrome P450-2C9
(CYP2C9 [MIM 601130]) and vitamin K epoxide reductase
complex subunit 1 (VKORC1 [MIM 608547]) genes alter
warfarin pharmacokinetics and pharmacodynamics, re-
spectively. In addition, environmental (e.g., vitamin K
intake, comedications, age, and body-surface area) and
other factors contribute to individual dose requirements,
and together the currently identiﬁed genetic and environ-
mental components account for approximately half of the
interindividual warfarin dose variation.2,4–7 Importantly,
dosing algorithms that incorporate several of these factors
and the variant CYP2C9 and VKORC1 genotypes recently
have been described.8,9
The variant CYP2C9*2 (p.R114C) and *3 (p.I359L)
alleles and the VKORC1 g.-1639G/A promoter polymor-
phism occur in patients who are drug ‘‘sensitive’’ and
require a lower average warfarin dose,10,11 whereas
VKORC1 missense mutations have been described in pa-
tients who are ‘‘resistant’’ and require higher warfarin
doses.12–17 To facilitate the use of CYP2C9 and VKORC1
genotyping in routine anticoagulation practice, it is impor-
tant to characterize the allele frequencies in various popu-
lations. Recently, we reported the CYP2C9, CYP2C19, and
CYP2D6 allele and genotype frequencies in 250 healthy
Ashkenazi Jewish (AJ) individuals.18 Here, we extend theseThe Amestudies to include the VKORC1 g.-1639G/A promoter
polymorphism (rs9923231), previously reported missense
mutations, p.V29L, p.A41S, p.V45A, p.R58G, p.V66M,
and p.L128R, and the recently described warfarin-resistant
p.D36Y missense mutation in a separate cohort of 260 AJ
and 80 Sephardic Jewish (SJ) individuals.
Peripheral blood samples were obtained with informed
consent from592unrelatedhealthyAJ and80SJ individuals
from the greater New York metropolitan area. All personal
identiﬁers were removed, the samples were tested anony-
mously, and genomic DNA was isolated with the Puregene
DNA Puriﬁcation kit (Gentra). Genotyping of six CYP2C9
alleles (*1, *2, *3, *4, *5, and *6), and sevenVKORC1 nucle-
otide variants (g.-1639G/A, g.85G/T [p.V29L], g.121G/
T [p.A41S], g.134T/C [p.V45A], g.172A/G [p.R58G],
g.1331G/A [p.V66M], and g.3487T/G [p.L128R]; Fig-
ure 1) was performed on 260 AJ and all 80 SJ individuals
with the Tag-ItMutationDetection Kit (LuminexMolecular
Diagnostics) according to the manufacturer’s instructions.
The CYP2C9 and VKORC1 genotypes for each sample were
determined with Tag-It Data Analysis Software (Luminex
Molecular Diagnostics), and the wild-type CYP2C9*1 allele
was assigned in the absence of other detectable variant
alleles.7 The CYP2C9 allele designations refer to those de-
ﬁned by the Cytochrome P450 Allele Nomenclature Com-
mittee,19 and representative heterozygous samples for all
identiﬁed alleles were conﬁrmed by direct sequencing.
The variant CYP2C9*2, *3, *4, *5, and *6 alleles have
been identiﬁed in individualswith impairedCYP2C9-medi-
atedmetabolism and lower warfarin dose requirements,4,201Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
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yet only the *2 and *3 alleles were identiﬁed in our healthy
AJ and SJ cohorts. When the CYP2C9 data from the 250 AJ
individuals reported previously18 were combined with the
results from the 260 AJ individuals studied here, the com-
bined AJ allele frequencies (n ¼ 510; Table 1) were distinct
from those in Asian and African American populations
and similar to those inotherpopulationswithEuropean an-
cestry.21 In contrast, the SJ cohort had signiﬁcantly higher
(p% 0.001)CYP2C9*2 and *3 allele frequencieswhen com-
pared to the AJ population, 0.194 and 0.144 versus 0.127
and 0.081, respectively (Table 1). On the basis of their ge-
notypes, the assigned CYP2C9 metabolic phenotypes11
among the AJ and SJ were distributed as extensive, interme-
diate, and poor metabolizers (Table 2). Given the increased
frequency of the deﬁcientCYP2C9*2 and *3 alleles in the SJ
cohort, thispopulationhad signiﬁcantlyhigher (p%0.002)
frequencies of intermediate and poor metabolizers when
compared to the AJ, 42.6% and 12.6% versus 32.4% and
4.7%, respectively (Table 2). Furthermore, the CYP2C9*2
and *3 allele frequencies observed in our SJ cohort were
considerably higher than those in other populations with
European ancestry.20,22 Given that CYP2C9*2 and *3 are
associated with an increased risk of excessive anticoagula-496 The American Journal of Human Genetics 82, 495–500, Februarytion and bleeding events among warfarin-treated pa-
tients,23,24 our results suggest that the SJ population is pre-
disposed to warfarin sensitivity when compared to other
populations with European ancestry.
Warfarin exerts its anticoagulant effect by inhibiting vi-
tamin K epoxide reductase, the catalytic subunit of which
is encoded by VKORC1, thereby preventing the regenera-
tion of vitamin K from vitamin K epoxide. After the iden-
tiﬁcation of VKORC1 in 2004,12,13 common VKORC1 poly-
morphisms and haplotypes that are strongly associated
with warfarin response were reported.4,25,26 Although the
molecular mechanisms by whichVKORC1 polymorphisms
modulate warfarin response remain unclear, recent evi-
dence suggests that the g.-1639G/A promoter polymor-
phism reduces hepatic VKORC1 expression and, therefore,
decreases warfarin dose requirements.10,26 The g.-1639G
promoter allele is present in the VKORC1*1, *3, and *4
haplotypes and is typically associated with a ‘‘normal’’ war-
farin dose.27,28 In contrast, the g.-1639A promoter allele,
which is in strong linkage disequilibrium with 6484C/T
(rs9934438), 6853G/C (rs8050894), and 7566C/T
(rs2359612; accession number AY587020),27 is present in
the VKORC1*2 haplotype17,27–29 and is consistentlyFigure 1. Schematic of the CYP2C9 and
VKORC1 Genes
The locations of the nucleotide variations and
missense mutations analyzed in this study are
noted and are based on accession numbers
M61857 and AY587020. The g.-1639G/A
(rs9923231), g.3730G/A (rs7294), and
g.698C/T (rs17708472) tag-SNPs for the
VKORC1*2,*3, and *4 haplotypes correspond to
3673G/A, 9041G/A, and 6009C/T (accession
number AY587020), respectively. Illustrations are
not to scale.Table 1. CYP2C9 and VKORC1 Allele Frequencies
AJa SJ
Allele Alleles Frequency 95% CI Alleles Frequency 95% CI
CYP2C9
*1 806 0.790 0.765–0.815 106 0.663c 0.589–0.763
*2 130 0.127 0.107–0.148 31 0.194c 0.133–0.255
*3 83 0.081 0.065–0.098 23 0.144c 0.089–0.198
*5 1 0.001 0.000–0.003 0 - -
VKORC1b
g.-1639G 277 0.533 0.490–0.576 80 0.500 0.423–0.577
g.-1639A 243 0.467 0.424–0.510 80 0.500 0.423–0.577
g.106G 1133 0.957 0.945–0.969 159 0.994d 0.982–1.000
g.106T (p.D36Y) 51 0.043 0.031–0.055 1 0.006d 0.000–0.018
a Combined AJ CYP2C9 data with Scott et al.18
b Based on accession number AY587020 (g.-1639G/A and g.106G/T correspond to 3673G/A and 5417G/T, respectively).
c p% 0.001.
d p% 0.025.2008
associated with warfarin-‘‘sensitive’’ individuals who re-
quire lower warfarin doses.6,7,9,30,31 Unlike African Ameri-
cans and similar to other individuals of European descent,27
the g.-1639A allele was present at high frequencies in both
our AJ (0.467) and SJ (0.500) cohorts (Table 1). Similar G/G,
G/A, and A/A genotype frequencies were observed in the
two Jewish subpopulations (Table 3), and they were compa-
rable to those reported in other individuals of European
descent.26,27 Interestingly, haplotype analysis based on
the PERLEGEN SNP public database indicates that the
g.-1639A allele is predominant in the Chinese population
(0.958),27 and such a ﬁnding is consistent with the lower
warfarin dose requirements typically observed in this
group.32
Heterozygous VKORC1 missense mutations have been
identiﬁed in individuals who are resistant to warfarin
and homozygousmutations have been reported in families
with combined deﬁciency of vitamin-K-dependent clot-
ting factors type 2 (MIM 607473).13,14 Although other
nongenetic factors can lead to increased warfarin doses
(e.g., excessive vitamin K intake, drug interactions, etc.),
heterozygous VKORC1 missense mutations alter vitamin
K epoxide reductase activity and, therefore, play a consider-








G/G 76 29.2 (28.4) 20 24.1 (26.2)
G/A 125 48.1 (49.8) 45 54.2 (50.0)
A/A 59 22.7 (21.8) 18 21.7 (23.8)
a Number of subjects.
b Predicted Hardy-Weinberg frequencies.The Ameable role in the warfarin-‘‘resistant’’ phenotype.13,14,16
However, these mutations presumably are rare given that
p.V29L, p.V45A, p.R58G, and p.L128R were not identiﬁed
in 384 healthy non-Jewish control chromosomes.13 More-
over, none of these and other (p.A41S and p.V66M) mis-
sense mutations were identiﬁed among the healthy AJ
and SJ individuals in our study.
The p.D36Y VKORC1 mutation was recently identiﬁed
in individuals who required an average warfarin dose
greater than 10 mg/day.17 This missense mutation is lo-
cated in the conserved lumenal loop (L1) VKORC1 region
that also contains p.V29L, p.A41S, p.V45A, p.R58G, and
p.V66M (Figure 1).13,33 For an analysis of VKORC1
p.D36Y in our AJ and SJ cohorts, a PCR-RFLP assay was em-
ployed17 with sense (50-AACCTGGAGATAATGGGCAGC
A-30) and antisense (50-ACACCGATCCCAGACTCCAGAA
TA-30) PCR primers and RsaI (New England BioLabs). The
frequency of p.D36Y in 100 AJ and 100 East African indi-
viduals was 0.040 and 0.150, respectively,17 and it had
a comparable allele frequency of 0.043 in our larger AJ co-
hort (n ¼ 592), and this was signiﬁcantly higher than that
observed among the SJ individuals (0.006; Table 1). The
high carrier frequency of p.D36Y in the AJ (1 in 12) indi-
cates that this population may be predisposed to warfarin
resistance.
Table 4 summarizes the combined CYP2C9 and VKORC1
genotype frequencies for the 260 AJ and 80 SJ cohorts,
which were in Hardy-Weinberg equilibrium. Predicted
CYP2C9 metabolizer phenotypes11 for both the AJ and SJ
were subdivided on the basis of VKORC1 g.-1639G/A
status and the presence of the p.D36Y warfarin-resistant
mutation. Although theVKORC1 phase could not be deter-
mined in our study, it is notable that no p.D36Y carriers
were identiﬁed in g.-1639A/A (VKORC1*2/*2) individuals,
suggesting that p.D36Y occurs on a g.-1639G backgroundTable 2. CYP2C9 Genotype Frequencies
AJa SJ
Predicted Metabolizer Phenotype/Genotype nb Observed (Expectedc) Frequency (%) nb Observed (Expectedc) Frequency (%)
Extensive (EM)
*1/*1 321 62.8 (62.5) 36 45.1d (43.9)
Intermediate (IM)
*1/*2 105 20.5 (20.1) 23 28.8 (25.7)
*1/*3 60 11.7 (12.8) 11 13.8 (19.0)
*1/*5 1 0.2 (0.2) 0 0 (0.0)
Total 166 32.4 (33.1) 34 42.6d (44.7)
Poor (PM)
*2/*2 6 1.2 (1.6) 1 1.3 (3.8)
*2/*3 13 2.5 (2.1) 6 7.5 (5.6)
*3/*3 5 1.0 (0.7) 3 3.8 (2.1)
Total 24 4.7 (4.4) 10 12.6d (11.5)
a Combined AJ CYP2C9 data with Scott et al.18
b Number of subjects.
c Predicted Hardy-Weinberg frequencies.
d p% 0.002.rican Journal of Human Genetics 82, 495–500, February 2008 497
(Table 4). Given that the VKORC1*3 and *4 haplotypes,
which are associated with ‘‘normal’’ warfarin dose require-
ments,28 also occur on a g.-1639G background,27 addi-
tional PCR-RFLP genotyping to identify these alleles was
performed on all p.D36Y carriers. Tag-SNPs 9041G/A
(rs7294; g.3730G/A) and 6009C/T (rs17708472;
g.698C/T; accession number AY587020; Figure 1)27
were interrogated for identiﬁcation of VKORC1*3 and *4
with sense (VKORC1*3: 50-TTTGCTTTGGCATGTGAGCCT
TGC-30; VKORC1*4: 50-GCATAATGACGGAATACAGAGGA
GGC-30) and antisense (VKORC1*3: 50-ACAGTCCATGGC
AGACACATGGTT-30; VKORC1*4: 50-GGTAGAGACAGGC
TTTCACCATGT-30) PCR primers and AciI and BfaI (New
England BioLabs), respectively. The VKORC1*1 haplotype
was assigned in the absence of other detectable alleles,
and representative p.D36Y, VKORC1*3, and *4 positive
samples were conﬁrmed by direct sequencing. Interest-
ingly, all the p.D36Y heterozygous individuals evaluated
in our AJ and SJ cohorts were heterozygotes for VKORC1*1
and *2, *3, or *4, and importantly, one AJ individual was
identiﬁed who was homozygous for both p.D36Y and
VKORC1*1 (data not shown). Thus, our ﬁndings strongly
support the hypothesis that p.D36Y tags a unique haplo-
type found on a VKORC1*1 background.17
Notably, patients with p.D36Y who have dose-reducing
variant CYP2C9*2, *3, or VKORC1*2 alleles still require
higher warfarin doses (>10 mg/day), indicating that this
missense mutation is ‘‘dominant’’ when present in indi-
viduals with warfarin-‘‘sensitive’’ CYP2C9 and VKORC1
alleles.17 Importantly, 11.3% of AJ individuals predicted
to be CYP2C9 extensive metabolizers and 8.7% of those
predicted to be intermediate and poor metabolizers were
VKORC1 p.D36Y carriers who would require markedly
higher warfarin doses (Table 4). Thus, ~10% of all AJ
individuals would be misclassiﬁed when only genotyping498 The American Journal of Human Genetics 82, 495–500, FebruaryCYP2C9*2, *3 and VKORC1 g.-1639G/A, thereby under-
scoring the importance of screening for p.D36Y prior to
initiating warfarin anticoagulation in AJ individuals.
The recently reportedwarfarin dosing algorithms that in-
corporate genotype information only include CYP2C9*2,
*3, andVKORC1 g.-1639G/A.8,9 On the basis of these dos-
ing guidelines and given that 211 AJ and 71 SJ individuals
had at least one variant CYP2C9 (*2 and *3) or VKORC1
(g.-1639G/A) allele, 81.2% of AJ and 88.8% of SJ individ-
uals would be candidates for genotype-based dose adjust-
ments (Table 4). The high frequency of variant CYP2C9
and VKORC1 alleles in AJ and SJ individuals indicates
that clinical testing of these genes is warranted among
individuals initiating warfarin therapy, as recently recom-
mended by a Food and Drug Administration Advisory
Committee (seeWeb Resources). Moreover, warfarin-‘‘resis-
tant’’ VKORC1missense mutations are currently not incor-
porated into published dosing algorithms, yet their identi-
ﬁcation prior to warfarin administration may reduce
complications because of ineffective anticoagulation. By
including p.D36Y in our analysis, 84.6% of AJ and 90.0%
of SJ individuals would beneﬁt from CYP2C9 and VKORC1
genotyping prior to initiating warfarin-based anticoagula-
tion. Further studies are necessary to correlate warfarin
dose requirements in patients with the p.D36Y allele and
various other CYP2C9 and VKORC1 alleles. Such informa-
tion is required to accurately model the contribution of
p.D36Y to warfarin dose for inclusion in warfarin dosing
algorithms for the AJ population.Acknowledgments
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